Rob Medcalf Is Working On a Novel Thrombolytic Drug
Monash Translational Medicine shared on LinkedIn:
”Time is brain’ when a person has a stroke.
But even when a patient receives medical attention within 60 minutes, that’s often not enough: tPA, the main drug currently used to treat acute ischemic stroke (the most common stroke type in Australia) isn’t effective for the majority of patients.
Professor Rob Medcalf, of the Australian Centre for Blood Diseases based at Monash Translational Medicine, is working on a novel thrombolytic (clot-busting) drug that could give many more stroke patients a better chance of recovery.
He’s been awarded two Monash University grants – from the Monash Research Impact Fund (MIRF) and the MNHS Commercialisation Incubator Program (MCIP) – to progress development of the drug.
”We desperately need more drug options to treat stroke, for the many patients who can’t go on TPA for reasons ranging from the other medications they’re on, to the short window for effective treatment,” Rob says.
‘These grants will help us address some of the challenges of bringing new drugs to market.”’
-
Nov 14, 2025, 11:58Marilena Vrana: Can Public-only Blood Collection Systems Meet the Growing Patient Need for PDMs?
-
Nov 14, 2025, 11:48Cedric Hermans Shares the 1st Illustrated Review Dedicated to Hemophilia B
-
Nov 14, 2025, 10:28Valance Washington: Proud to Share Our Lab’s Latest Publication in Platelets Journal
-
Nov 14, 2025, 10:18Sripal Bangalore and Ajay Kirtane on TUXEDO-2 Comparison Focusing on Diabetic Patients
-
Nov 14, 2025, 10:11Ashley Lawrenson on Her Coagulation Journey Using Automation With the HemoCell and HemoHub
-
Nov 14, 2025, 10:05Kingsley Wheaton: A Year Ago, Omni Was an Idea – Today, It’s a Movement!
-
Nov 14, 2025, 09:58Rucha Patil Takes The National DHR-ICMR Gold Award for Best Technology
-
Nov 14, 2025, 09:48Caitlin Raymond on ”The Plasma Chasers”
-
Nov 14, 2025, 09:42Erin VanDyke on Why They Do In-person Site Visits for NBCA Centers of Excellence Designation!